BMS sets up Roche, Pfizer rivalry with Turning Point takeove...

Bristol-Myers Squibb's all-cash offer for Turning Point Therapeutics – which values the biotech at $4.1 billion – bolsters its position in precision oncology and gives it a lead asset that